Management Is Clueless

Discussion in 'Teva Neuroscience' started by anonymous, Apr 8, 2020 at 8:36 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest


    Nice opinion, but Teva is moving into biologics and this is the only way to filter out all those primary care respiratory sample pushers. Gen-Pharma is done. If you're not moving into the specialty/biosimilar talent and pay scale level, you will be left behind.
     

  2. anonymous

    anonymous Guest

    Respiratory sample pushers?
    Nice coming from the Neuro Account Maintenance Crew.
    How long has it been since you actually sold something? Unless you were in early you were just riding that drug out - 10 to 2 everyday, lunch and done.
    If you are such a superior biologic sales force and all the Ajovy volume is coming thru Neuro - why is Ajovy coming in a distant third place?
     
  3. anonymous

    anonymous Guest

    It’s called terrible formulary coverage and no autoject until now. It still begs the question numb nuts, why do PCP reps account for only 5-10% of all Ajovy scripts?
     
  4. anonymous

    anonymous Guest

    Those sound like excuses for someone of your pay and talent level?
    Of the volume is less in PCP, they see less migraine patients and many if not most refer. That will change as their comfort level grows with use.
    Neuro will only see the most difficult patients as the class matures
     
  5. anonymous

    anonymous Guest

    We have very little to do. Also, dumb asses being non compliant so now we have even mess to do. I’m concerned we will not be able to do nothing and get paid much longer.
     
  6. anonymous

    anonymous Guest

    So, if you have three products that are similar and one has terrible formulary access and is harder to administer, you think anything other than third is doable? The fact is, the PCP reps aren’t pulling their weight. People keep saying all the business is going to be with the PCP offices. When will this drastic shift happen? You’re an idiot.
     
  7. anonymous

    anonymous Guest

    And you're a self inflated tool
    FYI Specialty to Neuro is a lateral move - no pay increase
    And you are not making anywhere near what a 'biologic' salesforce is, none of us are.
    Besides all that, I'm just glad we all still have jobs
    Go One Teva!
     
  8. anonymous

    anonymous Guest

    You just answered your question - Specialty is in the same boat - weak NC, formerly antiquated device with much less volume = less contribution. It may be longer than you expect but it will shift, hopefully they will combine salesforces.
     
  9. anonymous

    anonymous Guest

    People - time to face reality - Teva blows!
     
  10. anonymous

    anonymous Guest

    It is unbelievable that they would continue to have 2 sales forces when “Specialty” (aka primary care here) is worthless. Get rid of this dead weight.
     
  11. anonymous

    anonymous Guest

     
  12. anonymous

    anonymous Guest

    Neuro sales force accounts for 60% of the Ajovy volume. Specialty accounts for 36%. The remaining 4% come from "other" prescribers.
     
  13. anonymous

    anonymous Guest

    You were obviously smoking crack before you typed this! 36%!? That’s hysterical.
     
  14. anonymous

    anonymous Guest

    The numbers are not bearing out the use of the virtual engage details. People that are doing them are not increasing their numbers anymore than others. Some numbers are dropping.
     
  15. anonymous

    anonymous Guest

    It came straight from the national Sales Performance Summary. Emailed out each week.
    How about some more fun facts! Over the past 12 months, there are only 9,627 total targets writing.
    2,404 scripts came from the targets Specialty division calls on and 7,226 from Neuro division.
    That breaks down to 25% Specialty and 75% Neuro division. This is a very proportionate ratio between the 2 sales forces when you consider the concentration of migraine patients seen by a neuro vs primary care.
    TN sales force certainly produces the bulk of the TRXs, but the Specialty team is out cultivating new prescribers. The more collaboration between the divisions, positive results occur!
     
  16. anonymous

    anonymous Guest

    Anyone know when Teva’s hiring freeze will be over?
     
  17. anonymous

    anonymous Guest

    Got the green light for hire then position put on hold.
     
  18. anonymous

    anonymous Guest

    Thank you management. This message is so clearly written by someone in home office. The fact is many headache specialists are non-Neurologists which account for a ton of scripts. Take them out of the equation and Specialty is back down to 5%
     
  19. anonymous

    anonymous Guest

    Veeva Engage is the new company focus. Don't worry about seeing any doctors face to face going forward. They are tracking your virtual details. That is their focus.
     
  20. anonymous

    anonymous Guest

    Burnt a bridge over this already. Oh well, the price of meeting stats.